Understanding RRM1: Key Enzyme in DNA Replication (G6240)

Target Name: RRM1

NCBI ID: G6240

RRM1

Understanding RRM1: Key Enzyme in DNA Replication

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) is a protein that plays a crucial role in the process of DNA replication in eukaryotic cells. It is a key enzyme in the DNA replication machinery, responsible for the initiation of DNA replication at the site of a double -strand break. RRM1 is a 23-kDa protein that contains 155 amino acid residues. It is expressed in most eukaryotic cells and is involved in the regulation of DNA replication.

RRM1 is a member of the AIDA (Amino Acid-Induced Diffusion) family of proteins, which are characterized by the presence of a specific domain called the N-terminal hypervariable region (HVR). The HVR is a region of the protein that is highly variable and can be modified by various amino acids. This is important for the protein's ability to interact with various cellular signaling pathways and for its role in cellular signaling.

RRM1 is involved in the regulation of DNA replication in a variety of ways. One of its functions is to promote the formation of a double-strand break in response to DNA damage. This can be caused by various factors, such as exposure to ionizing radiation , UV radiation, or certain medications. When a double-strand break occurs, RRM1 helps to recruit the repair machinery to the site of the break and facilitates the formation of a stable double-strand.

RRM1 is also involved in the regulation of DNA replication in the context of gene expression. It has been shown to play a role in the regulation of gene expression by modulating the level of gene expression at different stages of the cell cycle. This is done by controlling the access of RNA polymerizers to the genomic DNA, which allows for the regulation of gene expression at the level of the gene.

RRM1 is also involved in the regulation of DNA replication in the context of cell division. It is a key enzyme in the G1 phase of cell division and is required for the completion of the replication of the genome in eukaryotic cells. In addition, RRM1 is involved in the regulation of the progression of mitosis (G1-G2-M) phase of cell division, which is characterized by the growth and preparation of the chromatin for cell division.

RRM1 is also a drug target and has been shown to be involved in various diseases. For example,RRM1 has been shown to be involved in the development and progression of certain types of cancer, such as breast cancer and colon cancer. It has also been shown to be involved in the regulation of aging and age-related diseases, such as Alzheimer's disease and Parkinson's disease.

In conclusion, RRM1 is a protein that plays a crucial role in the process of DNA replication in eukaryotic cells. It is involved in the regulation of DNA replication by promoting the formation of a double-strand break, regulating gene expression, and participating in the regulation of cell division. It is also a drug target and has been shown to be involved in various diseases. Further research is needed to fully understand the role of RRM1 in the regulation of DNA replication and its potential as a drug target.

Protein Name: Ribonucleotide Reductase Catalytic Subunit M1

Functions: Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides

The "RRM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets